People · Operator
Named in public records as an officer, director or promoter · active 2015–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Advantagene, Inc. | — | Biotechnology | Series B | $45.1M | $1.1B | 2015 |
Udi C. Merav at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Udi C. Merav on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen C. Rocamboli | 1 | 3 |
| Edward J Benz | 1 | 2 |
| Fred C. Mermelstein | 1 | 1 |
| Estuardo Aguilar-Cordova | 1 | 1 |
| Alan C. Smith | 1 | 1 |
| Mitchell C. Finer | 1 | 1 |
| Chris C. Martell | 1 | 1 |
| Paul C. Manning | 1 | 1 |
| Laura Aguilar | 1 | 1 |
| Sean C. Stalfort | 1 | 1 |
| Glenn C. Mattes | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.